Sponsors and Exhibitors. Recommended articles. Healthcare VC | Life sciences company creation | Former R&D leader, GenentechComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Lee-Karlon served as Chief Operating Officer of Altos Labs. One of many physiological findings about lipid–protein interaction is that lipid modifications regulate some proteins generated by cancer genes, says Rami Hannoush, a chemical biologist at the. Joel P. Rami Hannoush, Ph. D. PMID: 26080277 DOI: 10. ’s Post Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Question: Add details. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. -based biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular. D. D. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. The lipid-binding groove exhibits flexibility and spans both monomers,. Biography. Its proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific. Healthcare VC | Life sciences company creation 1wRami Hannoush, 45. Rami Hannoush, Ph. When expanded it provides a list of search options that will switch the search inputs to match the. hannoush. There are 3 professionals named "Rami Hannoush", who use LinkedIn to exchange information, ideas, and opportunities. The American Peptide Society, APS, a nonprofit scientific and educational organization founded in 1990, provides a forum for advancing and promoting knowledge of the chemistry and biology of peptides. Beitrag von Rami Hannoush, Ph. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho. EpiBiologics develops antibody-based targeted therapies against. Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Rami Hannoush serves as Venture Partner at Versant Ventures. Edit Recent News and Activity Section. Rami N. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 3mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. When expanded it provides a list of search options that will switch the search inputs to match the. Rami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. We cover Rami's new role at Versant, the founding story of. Welcome, Rami Hannoush, Ph. October 7-10, 2018 | Emerging Data on the Role of Wnt Biology in Cancer | 4 WEDNESDAY, OCTOBER 10 7:15 am Breakfast 9:00 am SESSION 8: Emerging Applications for Wnt Signaling in CancerRami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Corresponding author. Rami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. Proud to partner with a great team to systematically explore the untapped therapeutic potential of…“We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership. com. I am a Scientist in the Physiological Chemistry Department of Genentech's research organization. Contact Email [email protected] Abstract Protein palmitoylation plays diverse roles in regulating the trafficking, stability, and activity of cellular proteins. ’s Post Rami Hannoush, Ph. PMID: 30530496 PMCID: PMC6333880 Rami Hannoush, interim-CEO, said, “Since launching the company, the team at EpiBiologics has been able to further validate and industrialize the EpiTAC platform, creating a fit-for-purpose atlas of degraders. Its proprietary EpiTAC platform is a. ’s Post Rami Hannoush, Ph. That’s what it takes to walk across the stage as a Minds Matter NYC graduate. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 5mo Report this post Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. This past Saturday, the Class of 2023…Biomarker interview with Rami Hannoush, Ph. Supplementary Figures 1–7, Supplementary Tables 1–3 and Supplementary Methods. PubMed Abstract: Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5). Synthetic therapeutic peptides: science and market. Rami Nabil Hannoush, Rami Hannoush, Ramin Hannoush. Rami Hannoush, Ph. D. Recent News. Rami Hannoush’s Post. D. Rami Hannoush, Ph. D. Our group described u-alkyne fatty acids of various chain lengths (C10, C11, C13, C14, C16, and C18, with the alkyne group at the u position) (Figure 2) and showed the Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development. 1038/nprot. rami@gene. Founded in 2022 and led by CEO Dr. , Partner at Mubadala Capital, and Dr. Rami Hannoush’s Post Rami Hannoush General Partner, Mubadala Capital | Healthcare VC | Life sciences company creation 4d Report this post. Rami Hannoush, Ph. Rami Hannoush is the Chief Executive Officer (interim), President and a co-founder of EpiBiologics. D. D. A phone number associated with this person is (617) 576-7262 in the local area code 617. Back. 1038/s41589-018-0035-2 Abstract Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing. Connected to: Abdallah A Hannoush, 36 Rita P Hannoush, 28 Rola E Hannoush, 62 Krystal L Hannouz, 44 Donna L Hanns, 61 George E Hanns, 76 Jill R Hanns, 66 Lorca L Hanns, 66 Brenda J Hannula,. D. Yet, how different Wnts achieve various levels of signaling activation through distinct domains on LRP6 remains elusive. D. Marianne Mertens, [email protected]. Healthcare VC | Life sciences company creation | Former R&D leader, GenentechTimelines in Drug Development are more important than ever before. The . … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. PMID: 24292069. ’s Post Rami Hannoush, Ph. D General Information. Rami Hannoush, PhDPrincipal Scientist & Group Leader at Genentech. Expand search. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. com. Rami Hannoush, Ph. Supplementary Figure 3 S6Taught/moderated by Ryan Watts, founder/CEO of Denali Therapeutics, and Rami Hannoush, former senior scientist at Genentech and now a partner at Mubadala, who bring in former / current colleagues to introduce each of the major functions (e. D. Ribonucleic acids (RNA) are polymers of ribonucleotides linked together by 3',5. Expand search. D. ’s Post Rami Hannoush, Ph. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Anwesha Dey,4 Rami N. D. Chief Operating Officer (650) -. Healthcare VC | Life sciences company creation 6dTherapeutics. Hannoush include Harvard University & Scripps Research Institute. ’s Post Rami Hannoush, Ph. … | 79 تعليقات على LinkedInNatalia Arenas-Ramirez's 3 research works with 164 citations and 145 reads, including: Membrane targeting of palmitoylated Wnt and Hedgehog revealed by chemical probesgeneral partner at GV. D. The author has contributed to research in topics: Wnt signaling pathway & Frizzled. Healthcare VC | Life sciences company creation 2yThe 2020 Chemistry and Biology of Peptides Gordon Research Conference will showcase the most recent, cutting edge research in advancing peptides as tools, materials, and therapeutics. 1073/pnas. … | 77 comments on LinkedInRami N. The small size of the chemical tag is meant to minimize interference with fatty acyltransferase substrate recognition and catalytic efficiency (Hannoush, 2015, Hannoush and Arenas. Hannoush. Prior to his current role, he was a. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Phone and address: 35 28Th Ave #300, San Mateo, CA 94403. Genentech Inc. D. ’s Post Rami Hannoush, Ph. Jennifer Stockdill, Wayne State University. D. doi: 10. View Rami Hannoush's record in Watertown, MA including current phone number, address, relatives, background check report, and property record with Whitepages. Rami Hannoush has filed for patents to protect the following inventions. Baran . … | 80 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Expand search. D. Rami Hannoush is the Chief Executive Officer (interim), President and a co-founder of EpiBiologics. D. D. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 1y. , for the launch of [email protected]. D. Hannoush is an academic researcher from Genentech. Wnt ligands are critical for tissue homeostasis and form a complex with LRP6 and frizzled coreceptors to initiate Wnt/β-catenin signaling. Damtra, Masad (Supervisor) Abstract. Rami Hannoush, Ph. I had the pleasure to join Rob Faulkner and Soo. 4d Edited. Congratulations to Rami Hannoush, Ph. 1618293114 Abstract Frizzled (FZD) receptors mediate Wnt signaling in diverse processes ranging from bone growth to stem cell activity. com. 9:40 am - 10:05 am: Dinesh Patel (Protagonist Therapeutics Inc. Developing tool ligands that target individual LRP6 domains could help elucidate the mechanism of Wnt signaling regulation and uncover. Rami most recently served as a general partner at Mubadala Capital, building the firm’s healthcare platform in the U. Hannoush [email protected] Department of Early Discovery Biochemistry, Genentech, Inc. Rami N. D. There is no recent news or activity for this profile. , USA) "Orally Stable Peptides - Fact or Fiction? Or Discovery and Development of Orally Stable Peptides for Gastro-Intestinal (GI) Diseases"Dr. com. Biomarker interview with Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Rami Hannoush, Ph. hannoush. D. When expanded it provides a list of search options that will switch the search inputs to match the. Rami Hannoush, Ph. “Jim and I have known each other for the past 15 years through Genentech. PMID: 29632413 DOI: 10. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Leading strategies for expediting R&D and improving CMC efficiency. Connect Alison Symington Strategic expertise in bringing innovation in the life sciences. 4 the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, and hannoush. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 10mo EditedGreat chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 37 Kommentare auf LinkedInIn an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. 5 From the Section of Receptor Biology and Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden, the Faculty of Science, Institute of Experimental Biology, Masaryk. In 2021, when Genentech researcher and team leader Rami Hannoush was looking to leave his job at the South San Francisco biotechnology giant, an acquaintance reached out with a question. EpiBiologics Executive Team & Key Decision Makers. H. Lee-Karlon served as. One of many physiological findings about lipid–protein interaction is that lipid modifications regulate some proteins generated by cancer genes, says Rami Hannoush, a chemical biologist at the. Skip to main content Due to a planned power outage on Friday, 1/14, between 8am. D. cbpa. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. ’s Post Rami Hannoush, Ph. , Partner at Mubadala Capital, and Dr. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho Ventures, and existing investor Codon Capital. Previous affiliations of Rami N. Rami Hannoush, Ph. Rami N. Rami N. Our mission is to partner with visionary founders building enduring technology companies, and support them with Mubadala’s global scale. Jennifer Stockdill, Wayne State. D. Corresponding author. This button displays the currently selected search [email protected] Hannoush, Ph. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 3h Report this post. Back. D. … | 76 comments on LinkedInRami Hannoush, Ph. ’s Post Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Rami Hannoush, Ph. D. Rami Hannoush, education was also an escape. He brings a unique blend of investment experience and deep drug discovery expertise to our. Background. , 1 DNA Way, South San Francisco, CA 94080, USA. Dynasore inhibits cell proliferation of OS in vitro. Citizen and Immigration Services (USCIS) 2019 Outstanding. D. Rami N. D. D. Seminar Title: Challenging Targets and Emerging Approaches for Cellular Imaging in the Wnt Pathway, powered by Localist Event Calendar SoftwareRami Hannoush, Ph. Its proprietary EpiTAC platform is a. Search for a company, investor, advisor, limited partner, fund or professional to preview their profile. Verified email at post. The seven-transmembrane-spanning receptors of the FZD 1–10 class are bound and activated by the WNT family of lipoglycoproteins, thereby inducing a complex network of signaling pathways. D. 3 Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94080; hannoush. D. D. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. Additional Details: 1000 Ask Question Find a Lawyer. Contents: Chemical Synthesis S2 . Rami brings over 17 years of R&D experience at both large and small biotechnology companies. Biomarker interview with Rami Hannoush, Ph. Inventors: Eric Bourhis, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark. Healthcare VC | Life sciences company creation 6dGreat chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 37 comments on LinkedInRami Hannoush, Ph. Our mission is to partner with visionary founders building enduring technology companies, and support them with Mubadala’s global scale, resources. See the complete. Sponsors and Exhibitors. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. hannoush. Rami Hannoush, Ph. He also recently joined Versant Ventures (as a venture partner) where he works on biotech company creation and life science investments. ’s Post Rami Hannoush, Ph. Scroll Top. The author has an hindex of 28, co-authored 68 publications receiving 2989 citations. Back. ’s Post Rami Hannoush, Ph. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. … | 79 comments on LinkedInCongratulations to our own Rami Hannoush, Principal Scientist, Early Discovery Biochemistry, for being one of ten to receive the U. The author has contributed to research in topics: Wnt signaling pathway & Frizzled. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. 10. ’s Post Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. D. ’s Post Rami Hannoush, Ph. D. Rami Hannoush, Ph. PMID: 24292069 DOI: 10. This is a mechanism that's been conserved throughout the animal kingdom,” explains Rami Hannoush, interim CEO and co-founder of EpiBiologics. Rami Hannoush 5d · Edited Report this post Report Report. DOI: 10. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. … | 79 comments on LinkedInRami Hannoush, Ph. We are dedicated to bridging ideas from academia with the cutting edge in biotechnology and translation. Supplementary Text and Figures. ’s Post Rami Hannoush, Ph. chembiol. D. EpiBiologics's CEO is Rami Hannoush What does EpiBiologics do? Founded in 2022, EpiBiologics is a biotechnology company with a focus on antibody-based protein degradation. Hannoush and Arenas-Ramirez, 2009; Martin and Cravatt, 2009) also showed efficient bioorthogonal labeling of fatty acyl-ated proteins. Rami Hannoush, Genentech, South San Francisco, USA 5:25 pm General Discussion, Day 2 Wrap-Up 6:00 pm Reception, dinner . Aaron H Nile & Rami N Hannoush* Wnt proteins are critical regulators of signaling networks during embryonic development and in adult tissue homeostasis. D. ’s Post Rami Hannoush, Ph. Rami N Hannoush 1 Affiliation 1 Department of Early Discovery Biochemistry, Genentech, Inc. Operating Status Active. Vancouver, BC. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. D. Healthcare VC | Life sciences company creation 1yRami Hawash is the owner of a car mechanical repair business in Romford, Essex. The authors would like to acknowledge Dr. D. , USA) "Challenges and Emerging Approaches in Peptide Drug Discovery" 9:25 am - 9:40 am: Discussion. hannoush. Rami N. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Rami Hannoush, Ph. Manage my profile. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami N. Join to view full profile. D. Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Conference Description. Schedule view. has lived in San Mateo, CA Watertown, MA 1200 Massachusetts Ave, Cambridge, MA 02138 Foster City, CA. ”Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Hannoush and Phil S. Hannoush, Rami Nabil; Contributors. ’s Post Rami Hannoush, Ph. Rami Hannoush General Partner, Mubadala Capital | Life sciences company creation | Chief Scientific Officer 1y EditedRami Hannoush, Ph. D. Lives in San Mateo, CA. Exploiting these “natural” garbage routes to destroy pathogenic proteins is a well-accepted therapeutic strategy—especially for disordered targets, or those hidden within lipid membranes:. He is co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, MiNA Therapeutics Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Rami Hannoush: Chemical tools to perturb and image Wnt signaling: Danica Galonic Fujimori: 3/15/12: Harmit Malik, Fred Hutchinson Cancer Center: Genetic conflicts: the usual suspects and beyond: John Gross: 4/5/12: Ian Wilson, Scripps: Broad neutralization of HIV and influenza viruses: Bob Stroud:It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business. A. ’s Post Rami Hannoush, Ph. D. D. “Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression,” said Dr. Rami Hannoush, Ph. PMID: 28377511 PMCID: PMC5402412 DOI: 10. Reprints and Permissions. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 6mo Edited Report this post Great chat with. The company has headquarters in San Mateo, CA. We cover Rami's new role at Versant, the founding story of. Targeting the destruction of proteins, Peninsula biotech EpiBiologics raises $50M. He also recently joined Versant Ventures (as a venture partner) where he. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. It has been an incredible journey building this company. 05. Published on July 20, 2022. --,,. I had the pleasure to join Rob Faulkner and Soo Romanoff on a panel to talk about the #biotech. D. Last Funding Type Series A. The acquaintance was Jim Wells, a professor at the University of California San Francisco who had helped found Genentech’s protein engineering department. He also served as its founding Chief Scientific Officer and Chair of the Board of Directors since its inception. D. Born on September 20th, 1976 (47 years old)Rami Hannoush, Ph. Scalable Total Synthesis and Biological Evaluation of Haouamine A and Its Atropisomer. On average, Rami Hannoush works for one company for 2 years 7 months. … | 77 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. We cover Rami's new role at Versant, the founding story of. Rami Hannoush, Ph. teins generated by cancer genes, says Rami Hannoush, a chemical biologist at the biopharmaceutical company Genentech. Rami Hannoush, Ph. Symposium Sponsors. This button displays the currently selected search type. S. D. View the profiles of professionals named. It also regulates a plethora of processes during embryonic development, such as stem cell proliferation, migration, and differentiation. Electronic address: hannoush. Rami Hannoush, Ph. Thrilled to share this work from my former group at Genentech, reporting on a new class of peptide agonists that modulate. Rami Hannoush, Ph. Rami Hannoush, Ph. D. D. 05. D. This button displays the currently selected search type. D. edu - Homepage. Eric Shiozaki: Casdin Capital — BrightEdge Fund — Arkin Bio Ventures — Apollo Health Ventures . D. He brings a unique blend of investment experience and deep drug discovery expertise to our company creation efforts. , Partner at Mubadala Capital, and Dr. It’s been a terrific two days at #jpm2023, meeting new talent and connecting with friends in pharma and the VC world. D. ’s Post Rami Hannoush, Ph. The site facilitates. Funds will also. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. com. Rami Hannoush has 2 current jobs as General Partner at Mubadala Capital Ventures and Co-Founder at EpiBiologics. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. This button displays the currently selected search type. Introduction. Mr. Hannoush and Arenas-Ramirez, 2009; Martin and Cravatt, 2009) also showed efficient bioorthogonal labeling of fatty acyl-Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 4mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. Rami N Hannoush Adjunct Professor, Chemical and Systems Biology Operations Print Profile Email Profile Bio Bio Professional Contact. Rami Hannoush, Ph. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. We cover Rami's new role at Versant, the founding story of. 2 From the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080 hannoush.